02:10 AM EDT, 07/16/2026 (MT Newswires) -- Danish biotechnology company Gubra (GUBRA.CO) said Thursday its partner Boehringer Ingelheim began a phase 2 trial of its investigational obesity drug BI 3034701. The potential first-in-class therapy is a GLP-1/GIP/NYP2 receptor agonist designed to treat obesity through three complementary biological pathways. Gubra will receive a milestone payment of 10 million euros following the start of the study.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.